Noninfectious pulmonary complications after hematopoietic cell transplantation: a comprehensive review

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Respiratory medicine Pub Date : 2025-09-01 DOI:10.1016/j.rmed.2025.108336

Christopher Bertini , Felipe Soto , Rebecca Brown , Lara Bashoura , Guang-Shing Cheng , Matthew K. Hensley , Joe Hsu , Yu Kuang Lai , Husham Sharifi , Jeffrey M. Sturek , Gregory A. Yanik , Hemang Yadav , Saadia A. Faiz , Ajay Sheshadri

引用次数: 0

Abstract

Hematopoietic stem cell transplant (HSCT) is a cornerstone for the treatment of high-risk hematologic malignancies. The efficacy of HSCT is limited by transplant-related complications, particularly pulmonary complications. Broadly speaking, the myriads of non-infectious complications that occur after HSCT are less completely understood than infectious complications despite contributing to significant morbidity and mortality. This review covers all major non-infectious pulmonary complications (NIPCs), offering clinical context regarding NIPCs presentation and provoking events while highlighting pathogenesis, knowledge gaps, and emerging therapies.

查看原文本刊更多论文

造血细胞移植后的非感染性肺部并发症：一个全面的回顾。

造血干细胞移植（HSCT）是治疗高危血液系统恶性肿瘤的基石。移植相关并发症，尤其是肺部并发症，限制了造血干细胞移植的疗效。一般来说，与感染性并发症相比，HSCT后发生的无数非感染性并发症的发病率和死亡率较高，但人们对其了解较少。本综述涵盖了所有主要的非感染性肺并发症（NIPCs），提供了NIPCs表现和引发事件的临床背景，同时强调了发病机制、知识差距和新兴治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Respiratory medicine 医学-呼吸系统

CiteScore

7.50

自引率

0.00%

发文量

199

审稿时长

38 days

期刊介绍： Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants. Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.